The aim of the study is to evaluate the effects of local estriol treatment applied before vaginal repair surgery on steroid receptors, inflammatory cell response, vascular, connective and nervous tissues in the vagina, and its effects on early postoperative period pelvic floor functions, satisfaction with the surgery and vaginal health.

Start Date01 Apr 2024

Sponsor / Collaborator

Ankara University

NCT05562518 / RecruitingPhase 4IIT

GRACE-trial: a Randomized Active-controlled Trial for vulvovaGinal atRophy in breAst Cancer Patients on Endocrine Therapy.

In this prospective active-controlled randomized trial the investigators will assess for the first time ever the different local treatments of vulvovaginal atrophy in breast cancer patients on endocrine therapy. These patients are currently inadequately treated based on ignorance of possible treatment modalities and stigmatization of vulvovaginal atrophy.

Start Date21 Mar 2022

Sponsor / Collaborator

Ghent University Hospital

[+1]

NCT04735549 / CompletedNot Applicable

Correction of Vulvovaginal Atrophy in Postmenopausal Women Using Neodymium Laser Treatment

The aim of this prospective study is characteristic of changes in the vaginal wall and vulva after treatment of neodymium laser radiation with a wavelength of 1064 nm. To assess the condition of the vaginal walls and vulva before and after laser treatment, the following methods will be used: vaginal health index, perineometry, elastography of vulva, cytological methods. Female Sexual Function Index (FSFI), The Pelvic Organ Prolapse/Urinary Incontinence Sexual Questionnaire (PISQ-12), Vulvovaginal Symptoms Questionnaire (VSQ), Visual Analogue Scale (VAS) will be used to collect feedback on changes in the participants life quality. Total up to 120 participants with postmenopausal atrophy will be involved in the study. Participants will be divided into three groups: laser treatment group, topical hormones treatment group, and both laser treatment with topical hormones application group, by 40 participants in each. The time intervals between tests will be the same for all groups. Thus, a direct comparison between conventional treatment (topical hormones), laser treatment and combine laser and topical hormones therapy of the vaginal atrophy will be made. The main hypothesis of the study is improvement in condition of the vaginal walls after laser treatment and laser treatment with hormones application compared with the initial state of not less than thirty percent of participants, and improvement in condition on average compared with the hormones only therapy group.

Start Date01 Sep 2021

Sponsor / Collaborator

MeLSyTech, LLC

100 Clinical Results associated with Estriol

100 Translational Medicine associated with Estriol

100 Patents (Medical) associated with Estriol

4,873

Literatures (Medical) associated with Estriol

05 Jul 2024·Annual Review of Marine Science

A Global Inventory of Natural and Synthetic Estrogens in Aquatic Systems

Review

Author: Waniek, Joanna J ; Osterholz, Helena ; Frazão, Helena C

Estrogens are a group of endocrine disruptors that are recognized as a threat to the world's ecosystems and are easily transported through aquatic systems from mainly anthropogenic sources. To illustrate this growing problem, we have compiled a global overview of measured concentrations of natural and synthetic estrogens restricted to freshwater systems (lakes, rivers, and lagoons) and marine coastal and open ocean environments, focusing on estrone (E1), 17

$\upbeta$

-estradiol (E2), estriol (E3), and 17

$\upalpha$

-ethinylestradiol (EE2). We found that the cumulative risk quotient is high at 65% of 400 sampled sites, highlighting that estrogen pollution is a major environmental concern. Our investigation revealed that almost no information is available on the concentration levels of E1, E2, E3, and EE2 for the open ocean areas. However, their occurrence in all systems, including open seas, suggests that estrogens are not completely degraded during transport to and within the environment and may be more persistent than previously thought.

02 Jul 2024·Analytical Chemistry

Layer-By-Layer Designed Spark-Type AuCuPt Alloy with Robust Broadband Absorption to Enhance Sensitivity in Flexible Detection of Estriol by a Lateral Flow Immunoassay

Article

Author: Yin, Xuechi ; Ma, Jiaqi ; Liu, Huihui ; Wang, Chaoying ; Zhang, Daohong ; Wang, Jianlong ; Zhang, Qingzhe ; Wu, Qiaoying ; Youssef, Ahmed ; Cheng, Yuanyuan

Excessive intake of estrogen poses significant health risks to the human body; hence, there is a necessity to develop rapid detection methods to monitor its levels of addition. Gold nanoparticles (AuNPs), commonly utilized as colorimetric signal labels, find extensive application in lateral flow immunoassay (LFIA). However, the detection sensitivity of traditional AuNPs-LFIA is typically constrained by low molar extinction coefficients and reliance on a single signal. Herein, in this work, unique spark-type AuCuPt nanoflowers modified with tannic acid (AuCuPt@TA) were precisely designed by reasonable layer-by-layer element composition and green modification. The obtained AuCuPt displays robust broadband absorption spanning the visible to near-infrared spectrum, showcasing a notable molar extinction coefficient of 2.38 × 10¹² M^-1 cm^-1 and a photothermal conversion efficiency of 48.5%. Based on this, selecting estriol (E₃) as a model analyte, colorimetric/photothermal dual-signal LFIA (CLFIA and PLFIA) was developed. Limits of detection (LOD) of the CLFIA and PLFIA were achieved at 0.033 ng mL^-1 and 0.021 ng mL^-1, respectively, which represent a 9.3- and 14.6-fold improvement compared to the visual LOD of AuNPs-LFIA. Moreover, the application feasibility of the immunoassay was further evaluated in the milk and pork with satisfactory recoveries ranging from 86.21% to 117.91%. Thus, this work has enhanced the performance of LFIA for E₃ detection and exhibited enormous potential for other sensing platform construction.

01 Jul 2024·Analytical and Bioanalytical Chemistry

Novel ferrofluid based on hydrophobic deep eutectic solvents for separation and analysis of trace estrogens in environmental water and urine samples

Article

Author: Fan, Jing ; Li, Tiemei ; Shi, Longrui ; Liu, Enxiu ; Duan, Lichong

A novel ferrofluid prepared from a hydrophobic deep eutectic solvent (DES) and Fe₃O₄@graphite composite materials was introduced as a green microextraction medium for the separation and enrichment of trace estrogens in real samples. It was found that the ferrofluid greatly improved the capacity and selectivity of target analytes, benefiting from the enrichment of both DES and Fe₃O₄@graphite composite materials. Using a combination of high-performance liquid chromatography-fluorescence detection (HPLC-FLD) and vortex-assisted liquid-liquid microextraction (VALLME), a new method was established for simultaneous rapid processing and accurate determination of three estrogens (estradiol [E2], estriol [E3], and ethinyl estradiol [EE2]) in environmental water and urine samples. Key parameters affecting the extraction efficiency were optimized using a single-factor approach and response surface methodology. Under optimal conditions, this method yielded a low limit of detection (1.01 ng L^-1, 3.03 ng L^-1, and 25.0 ng L^-1 for EE2, E2, and E3, respectively), wide linear range (3-200,000 ng L^-1), high enrichment factors (9.81-47.2), and satisfactory recovery (73.8-129.0%). Compared with traditional analytical techniques, this method avoids the use of volatile toxic organic extraction solvents and cumbersome phase separation operations.

News (Medical) associated with Estriol

03 Apr 2023

·www.pharmaceutical-technology.com

New NHS Scheme cuts cost burden for hormone replacement therapies in the UK

Credit: Shutterstock/ Image Point Fr On April 1, the UK Department of Health and Social Care announced the launch of a new scheme to expand access to cheaper Hormone Replacement Therapy (HRT) drugs. The new HRT prepayment certificate ( PPC ) will reduce prescription costs to just £19.30 per year for HRT in the context of menopause. Free Report How is the Biopharmaceutical industry evolving? 2021 was a year of continued innovation and change in the Biopharmaceutical industry. As the COVID-19 pandemic continues to take its toll on businesses worldwide, it’s time to look for new ways to create value, prepare for the future, and remain competitive in the ever-changing landscape. GlobalData’s expansive report examines the business environment and trends that shape the Biopharmaceutical industry. We highlight the most impactful emerging technologies, as well as the industry, regulatory, and macroeconomic factors that influence growth prospects. Access the report to: Benchmark the impact of major themes on the Biopharmaceutical industry. Gain a deeper "on the ground" perspective through exclusive opinions and analysis from industry respondents. Evaluate the effects of COVID-19 on the sector. Download the full report to understand what to expect and how to align your strategies for success. By GlobalData Submit Country Code UK (+44) USA (+1) Algeria (+213) Andorra (+376) Angola (+244) Anguilla (+1264) Antigua & Barbuda (+1268) Argentina (+54) Armenia (+374) Aruba (+297) Australia (+61) Austria (+43) Azerbaijan (+994) Bahamas (+1242) Bahrain (+973) Bangladesh (+880) Barbados (+1246) Belarus (+375) Belgium (+32) Belize (+501) Benin (+229) Bermuda (+1441) Bhutan (+975) Bolivia (+591) Bosnia Herzegovina (+387) Botswana (+267) Brazil (+55) Brunei (+673) Bulgaria (+359) Burkina Faso (+226) Burundi (+257) Cambodia (+855) Cameroon (+237) Canada (+1) Cape Verde Islands (+238) Cayman Islands (+1345) Central African Republic (+236) Chile (+56) China (+86) Colombia (+57) Comoros (+269) Congo (+242) Cook Islands (+682) Costa Rica (+506) Croatia (+385) Cuba (+53) Cyprus North (+90392) Cyprus South (+357) Czech Republic (+42) Denmark (+45) Djibouti (+253) Dominica (+1809) Dominican Republic (+1809) Ecuador (+593) Egypt (+20) El Salvador (+503) Equatorial Guinea (+240) Eritrea (+291) Estonia (+372) Ethiopia (+251) Falkland Islands (+500) Faroe Islands (+298) Fiji (+679) Finland (+358) France (+33) French Guiana (+594) French Polynesia (+689) Gabon (+241) Gambia (+220) Georgia (+7880) Germany (+49) Ghana (+233) Gibraltar (+350) Greece (+30) Greenland (+299) Grenada (+1473) Guadeloupe (+590) Guam (+671) Guatemala (+502) Guinea (+224) Guinea - Bissau (+245) Guyana (+592) Haiti (+509) Honduras (+504) Hong Kong (+852) Hungary (+36) Iceland (+354) India (+91) Indonesia (+62) Iran (+98) Iraq (+964) Ireland (+353) Israel (+972) Italy (+39) Jamaica (+1876) Japan (+81) Jordan (+962) Kazakhstan (+7) Kenya (+254) Kiribati (+686) Korea North (+850) Korea South (+82) Kuwait (+965) Kyrgyzstan (+996) Laos (+856) Latvia (+371) Lebanon (+961) Lesotho (+266) Liberia (+231) Libya (+218) Liechtenstein (+417) Lithuania (+370) Luxembourg (+352) Macao (+853) Macedonia (+389) Madagascar (+261) Malawi (+265) Malaysia (+60) Maldives (+960) Mali (+223) Malta (+356) Marshall Islands (+692) Martinique (+596) Mauritania (+222) Mayotte (+269) Mexico (+52) Micronesia (+691) Moldova (+373) Monaco (+377) Mongolia (+976) Montserrat (+1664) Morocco (+212) Mozambique (+258) Myanmar (+95) Namibia (+264) Nauru (+674) Nepal (+977) Netherlands (+31) New Caledonia (+687) New Zealand (+64) Nicaragua (+505) Niger (+227) Nigeria (+234) Niue (+683) Norfolk Islands (+672) Northern Marianas (+670) Norway (+47) Oman (+968) Palau (+680) Panama (+507) Papua New Guinea (+675) Paraguay (+595) Peru (+51) Philippines (+63) Poland (+48) Portugal (+351) Puerto Rico (+1787) Qatar (+974) Reunion (+262) Romania (+40) Russia (+7) Rwanda (+250) San Marino (+378) Sao Tome & Principe (+239) Saudi Arabia (+966) Senegal (+221) Serbia (+381) Seychelles (+248) Sierra Leone (+232) Singapore (+65) Slovak Republic (+421) Slovenia (+386) Solomon Islands (+677) Somalia (+252) South Africa (+27) Spain (+34) Sri Lanka (+94) St. Helena (+290) St. Kitts (+1869) St. Lucia (+1758) Sudan (+249) Suriname (+597) Swaziland (+268) Sweden (+46) Switzerland (+41) Syria (+963) Taiwan (+886) Tajikstan (+7) Thailand (+66) Togo (+228) Tonga (+676) Trinidad & Tobago (+1868) Tunisia (+216) Turkey (+90) Turkmenistan (+7) Turkmenistan (+993) Turks & Caicos Islands (+1649) Tuvalu (+688) Uganda (+256) Ukraine (+380) United Arab Emirates (+971) Uruguay (+598) Uzbekistan (+7) Vanuatu (+678) Vatican City (+379) Venezuela (+58) Vietnam (+84) Virgin Islands - British (+1284) Virgin Islands - US (+1340) Wallis & Futuna (+681) Yemen (North)(+969) Yemen (South)(+967) Zambia (+260) Zimbabwe (+263) Country UK USA Afghanistan Åland Islands Albania Algeria American Samoa Andorra Angola Anguilla Antarctica Antigua and Barbuda Argentina Armenia Aruba Australia Austria Azerbaijan Bahamas Bahrain Bangladesh Barbados Belarus Belgium Belize Benin Bermuda Bhutan Bolivia Bonaire, Sint Eustatius and Saba Bosnia and Herzegovina Botswana Bouvet Island Brazil British Indian Ocean Territory Brunei Darussalam Bulgaria Burkina Faso Burundi Cambodia Cameroon Canada Cape Verde Cayman Islands Central African Republic Chad Chile China Christmas Island Cocos Islands Colombia Comoros Congo Democratic Republic of the Congo Cook Islands Costa Rica Côte d"Ivoire Croatia Cuba Curaçao Cyprus Czech Republic Denmark Djibouti Dominica Dominican Republic Ecuador Egypt El Salvador Equatorial Guinea Eritrea Estonia Ethiopia Falkland Islands Faroe Islands Fiji Finland France French Guiana French Polynesia French Southern Territories Gabon Gambia Georgia Germany Ghana Gibraltar Greece Greenland Grenada Guadeloupe Guam Guatemala Guernsey Guinea Guinea-Bissau Guyana Haiti Heard Island and McDonald Islands Holy See Honduras Hong Kong Hungary Iceland India Indonesia Iran Iraq Ireland Isle of Man Israel Italy Jamaica Japan Jersey Jordan Kazakhstan Kenya Kiribati North Korea South Korea Kuwait Kyrgyzstan Lao Latvia Lebanon Lesotho Liberia Libyan Arab Jamahiriya Liechtenstein Lithuania Luxembourg Macao Macedonia, The Former Yugoslav Republic of Madagascar Malawi Malaysia Maldives Mali Malta Marshall Islands Martinique Mauritania Mauritius Mayotte Mexico Micronesia Moldova Monaco Mongolia Montenegro Montserrat Morocco Mozambique Myanmar Namibia Nauru Nepal Netherlands New Caledonia New Zealand Nicaragua Niger Nigeria Niue Norfolk Island Northern Mariana Islands Norway Oman Pakistan Palau Palestinian Territory Panama Papua New Guinea Paraguay Peru Philippines Pitcairn Poland Portugal Puerto Rico Qatar Réunion Romania Russian Federation Rwanda Saint Helena, Ascension and Tristan da Cunha Saint Kitts and Nevis Saint Lucia Saint Pierre and Miquelon Saint Vincent and The Grenadines Samoa San Marino Sao Tome and Principe Saudi Arabia Senegal Serbia Seychelles Sierra Leone Singapore Slovakia Slovenia Solomon Islands Somalia South Africa South Georgia and The South Sandwich Islands Spain Sri Lanka Sudan Suriname Svalbard and Jan Mayen Swaziland Sweden Switzerland Syrian Arab Republic Taiwan Tajikistan Tanzania Thailand Timor-Leste Togo Tokelau Tonga Trinidad and Tobago Tunisia Turkey Turkmenistan Turks and Caicos Islands Tuvalu Uganda Ukraine United Arab Emirates US Minor Outlying Islands Uruguay Uzbekistan Vanuatu Venezuela Vietnam British Virgin Islands US Virgin Islands Wallis and Futuna Western Sahara Yemen Zambia Zimbabwe Kosovo By downloading this case study, you acknowledge that GlobalData may share your information with GlobalData and that your personal data will be used as described in their Privacy Policy Submit Visit our Privacy Policy for more information about our services, how GlobalData may use, process and share your personal data, including information on your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address. Thank you. Please check your email to download the Report. HRT is the primary treatment option for menopausal and perimenopausal women . It relieves symptoms such as hot flushes, night sweats, brain fog, joint pains, mood swings and vaginal dryness, by replacing hormones that may be at a lower level during menopause. HRT is also recommended for reducing the risk of hormone-related health problems such as osteoporosis and heart disease. Patients can now make a one-off payment of £19.30 annually to receive the benefits of the new PPC. The current standard NHS PPC costs £31.25 for three months or £111.60 for 12 months. Each item on an NHS prescription usually costs £9.65, so the new change should cut individual costs if a prescription for HRT drugs is filled three or more times in 12 months. HRT usually comprises of different forms of oestrogen and progesterone. Last year, UK regulators introduced serious shortage protocols (SSPs), in order to improve the supply of HRTs. These protocols restricted the dispensation of Besins Healthcare’s Oestrogel (estradiol), Aspen Pharmacare’s Ovestin (estriol) and Pfizer’s Premique Low Dose (medroxyprogesterone acetate) to a three months’ supply, to reduce drug shortages. The newly announced HRT PPC can be used against list of eligible HRT items that includes skin patches, tablets and topical preparations of the different hormones. This will include estradiols such as Theramex’s Evorel, Mylan’s Elleste-Solo, Gedeon Richter’s Lenzetto and Novartis ’s Estradot amongst others. In the context ofcombination HRT, Mylan’s Femoston, Novo Nordisk’s Kliovance and Trisequens will now be covered. The HRT PPC will be valid for 12 months and there is no limit placed on the number of times the certificate can be used before it expires. NHS PPCs are certificates that cover all NHS prescriptions for a set price. As per a survey published in the “Women’s Health Strategy for England ” report, respondents felt that access to appropriate menopause care was lacking. Furthermore, they reported a “reluctance among some healthcare professionals to prescribe HRT for menopause symptoms”. In the press release accompanying the announcement, the Health and Social Secretary Steve Barclay said, “Menopause care is essential healthcare, and we are ensuring cost is no longer a barrier to women getting the medicines they need”. Free Report How is the Biopharmaceutical industry evolving? 2021 was a year of continued innovation and change in the Biopharmaceutical industry. As the COVID-19 pandemic continues to take its toll on businesses worldwide, it’s time to look for new ways to create value, prepare for the future, and remain competitive in the ever-changing landscape. GlobalData’s expansive report examines the business environment and trends that shape the Biopharmaceutical industry. We highlight the most impactful emerging technologies, as well as the industry, regulatory, and macroeconomic factors that influence growth prospects. Access the report to: Benchmark the impact of major themes on the Biopharmaceutical industry. Gain a deeper "on the ground" perspective through exclusive opinions and analysis from industry respondents. Evaluate the effects of COVID-19 on the sector. Download the full report to understand what to expect and how to align your strategies for success. By GlobalData Submit Country Code UK (+44) USA (+1) Algeria (+213) Andorra (+376) Angola (+244) Anguilla (+1264) Antigua & Barbuda (+1268) Argentina (+54) Armenia (+374) Aruba (+297) Australia (+61) Austria (+43) Azerbaijan (+994) Bahamas (+1242) Bahrain (+973) Bangladesh (+880) Barbados (+1246) Belarus (+375) Belgium (+32) Belize (+501) Benin (+229) Bermuda (+1441) Bhutan (+975) Bolivia (+591) Bosnia Herzegovina (+387) Botswana (+267) Brazil (+55) Brunei (+673) Bulgaria (+359) Burkina Faso (+226) Burundi (+257) Cambodia (+855) Cameroon (+237) Canada (+1) Cape Verde Islands (+238) Cayman Islands (+1345) Central African Republic (+236) Chile (+56) China (+86) Colombia (+57) Comoros (+269) Congo (+242) Cook Islands (+682) Costa Rica (+506) Croatia (+385) Cuba (+53) Cyprus North (+90392) Cyprus South (+357) Czech Republic (+42) Denmark (+45) Djibouti (+253) Dominica (+1809) Dominican Republic (+1809) Ecuador (+593) Egypt (+20) El Salvador (+503) Equatorial Guinea (+240) Eritrea (+291) Estonia (+372) Ethiopia (+251) Falkland Islands (+500) Faroe Islands (+298) Fiji (+679) Finland (+358) France (+33) French Guiana (+594) French Polynesia (+689) Gabon (+241) Gambia (+220) Georgia (+7880) Germany (+49) Ghana (+233) Gibraltar (+350) Greece (+30) Greenland (+299) Grenada (+1473) Guadeloupe (+590) Guam (+671) Guatemala (+502) Guinea (+224) Guinea - Bissau (+245) Guyana (+592) Haiti (+509) Honduras (+504) Hong Kong (+852) Hungary (+36) Iceland (+354) India (+91) Indonesia (+62) Iran (+98) Iraq (+964) Ireland (+353) Israel (+972) Italy (+39) Jamaica (+1876) Japan (+81) Jordan (+962) Kazakhstan (+7) Kenya (+254) Kiribati (+686) Korea North (+850) Korea South (+82) Kuwait (+965) Kyrgyzstan (+996) Laos (+856) Latvia (+371) Lebanon (+961) Lesotho (+266) Liberia (+231) Libya (+218) Liechtenstein (+417) Lithuania (+370) Luxembourg (+352) Macao (+853) Macedonia (+389) Madagascar (+261) Malawi (+265) Malaysia (+60) Maldives (+960) Mali (+223) Malta (+356) Marshall Islands (+692) Martinique (+596) Mauritania (+222) Mayotte (+269) Mexico (+52) Micronesia (+691) Moldova (+373) Monaco (+377) Mongolia (+976) Montserrat (+1664) Morocco (+212) Mozambique (+258) Myanmar (+95) Namibia (+264) Nauru (+674) Nepal (+977) Netherlands (+31) New Caledonia (+687) New Zealand (+64) Nicaragua (+505) Niger (+227) Nigeria (+234) Niue (+683) Norfolk Islands (+672) Northern Marianas (+670) Norway (+47) Oman (+968) Palau (+680) Panama (+507) Papua New Guinea (+675) Paraguay (+595) Peru (+51) Philippines (+63) Poland (+48) Portugal (+351) Puerto Rico (+1787) Qatar (+974) Reunion (+262) Romania (+40) Russia (+7) Rwanda (+250) San Marino (+378) Sao Tome & Principe (+239) Saudi Arabia (+966) Senegal (+221) Serbia (+381) Seychelles (+248) Sierra Leone (+232) Singapore (+65) Slovak Republic (+421) Slovenia (+386) Solomon Islands (+677) Somalia (+252) South Africa (+27) Spain (+34) Sri Lanka (+94) St. Helena (+290) St. Kitts (+1869) St. Lucia (+1758) Sudan (+249) Suriname (+597) Swaziland (+268) Sweden (+46) Switzerland (+41) Syria (+963) Taiwan (+886) Tajikstan (+7) Thailand (+66) Togo (+228) Tonga (+676) Trinidad & Tobago (+1868) Tunisia (+216) Turkey (+90) Turkmenistan (+7) Turkmenistan (+993) Turks & Caicos Islands (+1649) Tuvalu (+688) Uganda (+256) Ukraine (+380) United Arab Emirates (+971) Uruguay (+598) Uzbekistan (+7) Vanuatu (+678) Vatican City (+379) Venezuela (+58) Vietnam (+84) Virgin Islands - British (+1284) Virgin Islands - US (+1340) Wallis & Futuna (+681) Yemen (North)(+969) Yemen (South)(+967) Zambia (+260) Zimbabwe (+263) Country UK USA Afghanistan Åland Islands Albania Algeria American Samoa Andorra Angola Anguilla Antarctica Antigua and Barbuda Argentina Armenia Aruba Australia Austria Azerbaijan Bahamas Bahrain Bangladesh Barbados Belarus Belgium Belize Benin Bermuda Bhutan Bolivia Bonaire, Sint Eustatius and Saba Bosnia and Herzegovina Botswana Bouvet Island Brazil British Indian Ocean Territory Brunei Darussalam Bulgaria Burkina Faso Burundi Cambodia Cameroon Canada Cape Verde Cayman Islands Central African Republic Chad Chile China Christmas Island Cocos Islands Colombia Comoros Congo Democratic Republic of the Congo Cook Islands Costa Rica Côte d"Ivoire Croatia Cuba Curaçao Cyprus Czech Republic Denmark Djibouti Dominica Dominican Republic Ecuador Egypt El Salvador Equatorial Guinea Eritrea Estonia Ethiopia Falkland Islands Faroe Islands Fiji Finland France French Guiana French Polynesia French Southern Territories Gabon Gambia Georgia Germany Ghana Gibraltar Greece Greenland Grenada Guadeloupe Guam Guatemala Guernsey Guinea Guinea-Bissau Guyana Haiti Heard Island and McDonald Islands Holy See Honduras Hong Kong Hungary Iceland India Indonesia Iran Iraq Ireland Isle of Man Israel Italy Jamaica Japan Jersey Jordan Kazakhstan Kenya Kiribati North Korea South Korea Kuwait Kyrgyzstan Lao Latvia Lebanon Lesotho Liberia Libyan Arab Jamahiriya Liechtenstein Lithuania Luxembourg Macao Macedonia, The Former Yugoslav Republic of Madagascar Malawi Malaysia Maldives Mali Malta Marshall Islands Martinique Mauritania Mauritius Mayotte Mexico Micronesia Moldova Monaco Mongolia Montenegro Montserrat Morocco Mozambique Myanmar Namibia Nauru Nepal Netherlands New Caledonia New Zealand Nicaragua Niger Nigeria Niue Norfolk Island Northern Mariana Islands Norway Oman Pakistan Palau Palestinian Territory Panama Papua New Guinea Paraguay Peru Philippines Pitcairn Poland Portugal Puerto Rico Qatar Réunion Romania Russian Federation Rwanda Saint Helena, Ascension and Tristan da Cunha Saint Kitts and Nevis Saint Lucia Saint Pierre and Miquelon Saint Vincent and The Grenadines Samoa San Marino Sao Tome and Principe Saudi Arabia Senegal Serbia Seychelles Sierra Leone Singapore Slovakia Slovenia Solomon Islands Somalia South Africa South Georgia and The South Sandwich Islands Spain Sri Lanka Sudan Suriname Svalbard and Jan Mayen Swaziland Sweden Switzerland Syrian Arab Republic Taiwan Tajikistan Tanzania Thailand Timor-Leste Togo Tokelau Tonga Trinidad and Tobago Tunisia Turkey Turkmenistan Turks and Caicos Islands Tuvalu Uganda Ukraine United Arab Emirates US Minor Outlying Islands Uruguay Uzbekistan Vanuatu Venezuela Vietnam British Virgin Islands US Virgin Islands Wallis and Futuna Western Sahara Yemen Zambia Zimbabwe Kosovo By downloading this case study, you acknowledge that GlobalData may share your information with GlobalData and that your personal data will be used as described in their Privacy Policy Submit Visit our Privacy Policy for more information about our services, how GlobalData may use, process and share your personal data, including information on your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address. Thank you. Please check your email to download the Report.

04 Nov 2022

·www.sciencedaily.com

Researchers offer roadmap for identifying new neuroprotective treatments by leveraging sex differences

Sex differences in the aging brain may offer an enticing clue for developing more effective neuroprotective treatments, according to a new research strategy. A new study from UCLA researchers provides a strategy for finding treatments optimally tailored for women and men to prevent cognitive decline in aging as well as progression of neurodegenerative diseases by leveraging sex differences in the brain. Aging is associated with cognitive decline and brain atrophy. Aging also confers a major risk for developing a neurodegenerative disease. Given the aging population, novel strategies are needed to identify neuroprotective therapeutics. The study of sex differences in brain aging and neurodegenerative diseases can reveal new candidate treatment targets tailored for women and men. Understanding the role of sex chromosome gene expression in the brain in the context of waning sex hormones during aging is a new approach to identifying neuroprotective treatments. Dr. Rhonda Voskuhl, Professor, and Dr. Yuichiro Itoh, Associate Researcher, in the Department of Neurology, have created a roadmap to identify novel neuroprotective treatments tailored for women and men that leverage known sex differences in brain aging and neurodegenerative diseases. Previously, research pursuing treatments for neurodegenerative diseases ignored sex differences in the brain and pooled data together from males and females, taking a "one size fits all" approach. This could dilute out robust effects that exist in one sex but not the other at the clinical research level and fail to capitalize on known disease modifiers in the discovery of new treatment targets at the basic research level. In their study, "The X factor in neurodegeneration," Voskuhl and Itoh write that known sex differences in the brain as well as the effect of higher expression of certain X chromosome genes in females (XX) compared to males (XY) can be assessed for their role in neurodegeneration during aging, a stage of life characterized by loss of potentially neuroprotective hormones in females (estrogen in menopause) and males (testosterone in andropause). The study offers a roadmap for disentangling the contribution of these sex-specific factors, which can yield treatments optimized and targeted for each sex. In the future, this roadmap can be used by researchers to discover targets on the X chromosome gene for development of modulatory treatments that prevent neurodegeneration and promote neural repair during brain aging. "Given the aging population and lack of treatments to prevent cognitive decline during health and to reduce the risk for developing neurodegenerative diseases, it is now imperative to apply new strategies to identify neuroprotective treatments," said Voskuhl, who also directs the UCLA Multiple Sclerosis Program. "Leveraging what is known about sex differences in multiple sclerosis, Alzheimer's disease, and Parkinson's disease can reveal candidate treatment targets tailored for women and men affected by these conditions. Sex chromosome effects remain understudied and represent a promising frontier for discovery, particularly in the context of declining levels of sex hormones during menopause and andropause." Voskuhl discloses being an inventor on patents owned by UCLA that involve estriol and estrogen receptor beta ligand treatments to maintain cognitive function during aging and neurodegenerative disease. Itoh has no conflicts of interest to disclose.

100 Deals associated with Estriol

External Link

KEGG	Wiki	ATC	Drug Bank
D00185	Estriol	G03CC06 G03CA04	DB04573

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Infertility	CN	-	01 Jan 2000
Vulvovaginal atrophy	GB	Aspen Pharma Trading Ltd.	20 Aug 1982
Osteoporosis	JP	Mochida Pharmaceutical Co., Ltd.	28 Dec 1981
Female Urogenital Diseases	JP	ASKA Pharmaceutical Co., Ltd.	27 Sep 1972
Menopausal symptoms	JP	Mochida Pharmaceutical Co., Ltd.	18 Nov 1960
Uterine Cervical Erosion	JP	Mochida Pharmaceutical Co., Ltd.	18 Nov 1960
Uterine Cervicitis	JP	Mochida Pharmaceutical Co., Ltd.	18 Nov 1960
Vaginitis	JP	Mochida Pharmaceutical Co., Ltd.	18 Nov 1960

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Atrophic Vaginitis	NDA/BLA	SE	ITF Research Pharma SLU	16 Oct 2015
Atrophic Vaginitis	NDA/BLA	ES	ITF Research Pharma SLU	16 Oct 2015
Early Stage Breast Carcinoma	NDA/BLA	SE	ITF Research Pharma SLU	16 Oct 2015
Early Stage Breast Carcinoma	NDA/BLA	ES	ITF Research Pharma SLU	16 Oct 2015
vaginal mucosa dry	Phase 1	HU	ITF Research Pharma SLU	01 Oct 2016
vaginal mucosa dry	Phase 1	SE	ITF Research Pharma SLU	01 Oct 2016
vaginal mucosa dry	Phase 1	IT	ITF Research Pharma SLU	01 Oct 2016
Vulvovaginal atrophy	Phase 1	ES	ITF Research Pharma SLU	16 Oct 2015
Vulvovaginal atrophy	Phase 1	SE	ITF Research Pharma SLU	16 Oct 2015
Multiple Sclerosis	Preclinical	US	Theriva Biologics, Inc.	-

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04574999 (CTgov)	Phase 3	Vulvovaginal atrophy \| Postmenopausal atrophic vaginitis	167	Estriol (0.005% Estriol Group)	zvkpqlzzjn(oklkcqsoag) = rwhdfjuqmj crbgdwhqrw (cnvolnczde, qxhinpbusl - hytrjriqsh) View more	-	11 Dec 2020
				Placebo (Placebo Group)	zvkpqlzzjn(oklkcqsoag) = mgdjzccsxf crbgdwhqrw (cnvolnczde, vuhuvdhfvl - dslqrmvdet) View more
NCT02967510 (CTgov)	Phase 2	Vulvovaginal atrophy \| vaginal mucosa dry	283	Estriol (Estriol 0.005%)	fewzhiofrj(xziwqekpis) = kiwzxrtudf dyiofcrxqh (oswrjacggc, owlyrojppl - vcvabvregf) View more	-	25 Sep 2019
				Estriol (Estriol 0.002%)	fewzhiofrj(xziwqekpis) = eqvopjvjlx dyiofcrxqh (oswrjacggc, fikvtvnltt - kpewgnfsnf) View more
NCT02413008 (BLISSAFE, CTgov)	Phase 2	Vulvovaginal atrophy \| Early Stage Breast Carcinoma	61	estriol (0.005% Estriol Vaginal Gel)	yferjfrmwc(gmqyhczuwe) = xyrcsdkhxp uwlcdboert (mcdsaofddb, vlgczspcpc - bjaqsnzggh) View more	-	05 Aug 2019
				Placebo (Placebo Vaginal Gel)	yferjfrmwc(gmqyhczuwe) = hyxmdrbxjw uwlcdboert (mcdsaofddb, rhsjdacoxd - zlpazhtyem) View more
NCT01408030 (NOSE, CTgov)	Phase 2	Telangiectasia, Hereditary Hemorrhagic \| Epistaxis	123	Bevacizumab (Bevacizumab Spray)	twaxsndsqo(odbwkmqarc) = xgqrllmvmy osfcyqrdwc (vmaqzzzxkz, ipmkgaqpie - qxugvlknjr) View more	-	19 Oct 2018
				Estriol (Estriol Spray)	twaxsndsqo(odbwkmqarc) = bkaxvwwhru osfcyqrdwc (vmaqzzzxkz, nqzshcucgo - ubljnslado) View more
NCT00302731 (CTgov)	Phase 2	-	21	placebo+progesterone+conjugated equine estrogens+estradiol (Study Arm 1)	zpvzlstxss(ojrtvdlyun) = fulqjogwzg jtawdjggsi (jdtckzkbuk, vagufbcdtd - bvxuzorbga) View more	-	16 May 2018
				placebo+estriol+progesterone+estradiol (Study Arm 2)	zpvzlstxss(ojrtvdlyun) = fmbwjiehat jtawdjggsi (jdtckzkbuk, nmyikswood - gssaeirkco) View more
NCT00451204 (Estriol-MS, CTgov)	Phase 2	Multiple Sclerosis, Relapsing-Remitting \| Multiple sclerosis relapse	158	Estriol+Copaxone (Estriol Capsules Plus Copaxone Injections)	gmctcgqdft(efazgtnefh) = rozrlxebwh kwiqercryi (ozetielhhw, ptjacqrzkx - vizatkgbuv) View more	-	16 Jun 2016
				Placebo+Copaxone (Placebo Capsules Plus Copaxone Injections)	gmctcgqdft(efazgtnefh) = flkhvqdwtz kwiqercryi (ozetielhhw, kvytyuwzpk - hugcynoolf) View more
NCT00451204 (Pubmed \| Lancet Neurol) Manual	Phase 2	Multiple Sclerosis, Relapsing-Remitting	164	glatiramer acetate+Estriol	(vxmlvnqitc) = hzqgmrszge lwogelwmct (vuckseqcom, 0.17 - 0.37) View more	Positive	01 Jan 2016
				Placebo	(vxmlvnqitc) = afsgpqfhuf lwogelwmct (vuckseqcom, 0.25 - 0.53) View more
NCT00816556 (CTgov)	Phase 3	Atrophic Vaginitis	63	Estriol (Estriol)	ipbblzbrea(snukchphih) = tzbhlvrawa llcaoueqex (ffypfxnhzi, etkutwouip - riqxzxkuco) View more	-	28 Mar 2014
				estradiol valerate (Estradiol)	ipbblzbrea(snukchphih) = uskjqzleru llcaoueqex (ffypfxnhzi, osuxewpokl - hkcyzutenm) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis